What is the recommended hepatitis C antiviral regimen for a patient with decompensated cirrhosis (Child‑Pugh class B/C), hemoglobin 7 g/dL, bilirubin 13.5 mg/dL, and INR 2.5?

Treatment Recommendation for Decompensated Cirrhosis (Child-Pugh B/C)

For this patient with decompensated cirrhosis (Child-Pugh B/C), hemoglobin 7 g/dL, bilirubin 13.5 mg/dL, and INR 2.5, the treatment of choice is sofosbuvir/velpatasvir for 12 weeks WITH ribavirin, starting ribavirin at 600 mg daily and adjusting based on tolerance given the severe anemia. 1

Critical Contraindications

Protease inhibitors are absolutely contraindicated in this patient. The presence of decompensated cirrhosis (Child-Pugh B or C) makes glecaprevir/pibrentasvir and any protease inhibitor-containing regimen unsafe due to substantially higher drug exposure and risk of toxicity 1. This is an A1 level recommendation from EASL 2020 guidelines.

Recommended Regimen

Primary Treatment Option

• Sofosbuvir (400 mg) / Velpatasvir (100 mg) fixed-dose combination for 12 weeks
• Plus weight-based ribavirin (1000 mg if <75 kg, 1200 mg if ≥75 kg) 1

Critical Modification for This Patient

Given the hemoglobin of 7 g/dL, start ribavirin at 600 mg daily and adjust upward based on tolerance 2. This reduced starting dose is specifically recommended for decompensated cirrhosis patients in the guidelines 2.

Evidence Supporting Ribavirin Addition

The ASTRAL-4 study demonstrated clear benefit of adding ribavirin in decompensated cirrhosis 1:

• Without ribavirin (12 weeks): SVR rates 50-100% depending on genotype
• With ribavirin (12 weeks): SVR rates 85-100% across genotypes
• Most dramatic improvement seen in genotype 3 (50% → 85% SVR)

The benefit of ribavirin has been confirmed in real-world cohorts from the United States Chronic Hepatitis Cohort Study 1.

Alternative if Ribavirin Contraindicated

If ribavirin cannot be used due to the severe anemia (Hgb 7 g/dL) or is poorly tolerated:

• Sofosbuvir/velpatasvir for 24 weeks WITHOUT ribavirin 2
• This is a B1/B2 recommendation for patients with contraindications or poor tolerance to ribavirin

Treatment Setting and Monitoring

This patient MUST be treated in an experienced center with easy access to liver transplantation 1. The combination of:

• Bilirubin 13.5 mg/dL (markedly elevated)
• INR 2.5 (significantly prolonged)
• Hemoglobin 7 g/dL (severe anemia)

...indicates advanced decompensation requiring close monitoring with the possibility of stopping therapy if worsening decompensation occurs during treatment 1.

Specific Monitoring Requirements

• Frequent clinical and laboratory assessment is mandatory (B2 recommendation) 2
• Monitor for further hepatic decompensation
• Monitor hemoglobin closely if ribavirin is used
• Assess for hypoglycemia if patient has diabetes
• Monitor INR if patient takes warfarin

Genotype-Specific Considerations

While the question doesn't specify genotype, the regimen varies slightly:

• Genotypes 1,2,4,5,6: 12 weeks with ribavirin 1, 2
• Genotype 3: 24 weeks with ribavirin (due to lower SVR rates) 2

Expected Outcomes

SVR Rates

Patients with decompensated cirrhosis achieve SVR rates of 88-100% with sofosbuvir-based regimens plus ribavirin, though rates are lower than in compensated cirrhosis 3, 4.

Liver Function Improvement

• One-third to one-half of patients show significant improvements in bilirubin, albumin, INR, and MELD scores 2
• 46% of Child-Pugh B patients who achieve SVR regress to Child-Pugh A 5
• Improvement occurs more frequently in Child-Pugh B than Child-Pugh C patients 2

Prognostic Factors

Baseline factors predicting poor response or further decompensation 3:

• Albumin <3.5 g/dL (this patient likely has low albumin given INR 2.5 and bilirubin 13.5)
• MELD score >14
• Genotype 3 infection

The presence of ascites is independently associated with no improvement in liver function even after achieving SVR 5.

Common Pitfalls to Avoid

1. Never use protease inhibitors in decompensated cirrhosis—this includes glecaprevir/pibrentasvir despite its pangenotypic activity
2. Do not start full-dose ribavirin in patients with baseline anemia—start at 600 mg daily
3. Do not treat in community settings—these patients require tertiary care with transplant access
4. Do not assume SVR equals clinical improvement—only 30-50% show meaningful liver function improvement 1, 5

Transplant Considerations

Given the severity of decompensation (bilirubin 13.5, INR 2.5), calculate the MELD score:

• If MELD ≥18-20: Consider transplanting first and treating HCV post-transplant 2
• If MELD <18-20: Treat now and reassess for potential delisting if significant improvement occurs 2, 1

Real-world data shows 15.5-49% of patients awaiting transplant no longer require it after successful DAA therapy 1, 4, though patients with MELD >20 are rarely delisted 1.